Braftovi

Active Ingredient(s): Encorafenib
FDA Approved: * June 27, 2018
Pharm Company: * ARRAY BIOPHARMA INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Braftovi Overview

Encorafenib, also known as Braftovi and LGX818 is a drug for the treatment of certain melanomas. It is a small molecule BRAF inhibitor [1] that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.[2] The substance was being developed by Novartis and then by Array BioPharma. In June 2018 it was approved by the FDA in combination with binimetinib for the treatment of patients w...

Read more Braftovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Encorafenib

Recent Braftovi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Encorafenib
  • Capsule: 50mg, 75mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Braftovi: (2 results)

Sorted by National Drug Code
  • 70255-020 Braftovi 50 mg Oral Capsule by Array Biopharma Inc.
  • 70255-025 Braftovi 75 mg Oral Capsule by Array Biopharma Inc.

Other drugs which contain Encorafenib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 November 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA